Objective: HIV-1 infection of macrophages increases cathepsin B secretion and induces neuronal apoptosis, but the molecular mechanism remains unclear.
Introduction
During HIV-1 infection, monocytes cross the blood-brain barrier (BBB) into the central nervous system (CNS) facilitating viral spread into microglia and astrocytes, unleashing a persistent inflammatory response and neuronal damage [1] [2] [3] [4] [5] [6] [7] . The inflammation leads to HIV-associated encephalitis (HIVE) and neurological complications known as HIV-associated neurocognitive disorders (HANDs). Clinical manifestations range from asymptomatic to the severe form HIV-associated dementia (HAD).
Cathepsin B, a lysosomal cysteine protease, is upregulated and secreted from HIV-infected macrophages [7] [8] [9] . The interaction of cathepsin B with its endogenous inhibitors cystatins B and C is disrupted by HIV infection [7] [8] [9] . Notably, cathepsin B present in macrophage-conditioned medium (MCM) contributes to 10-20% of neuronal apoptosis [7] . Cathepsin B has been correlated to amyloid plaque accumulation [10] [11] [12] [13] , as well as to its degradation [14] , being linked to Alzheimer's disease [15] . Cathepsin B can interact with matrix metalloproteases (MMPs) at the extracellular level, suggesting a possible role in cellular migration, tissue remodelling and cancer [16] [17] [18] [19] .
We sought to determine whether cathepsin B secreted from HIV-infected macrophages interacts with additional proteins at the extracellular level to promote neuronal apoptosis. Cathepsin B was immunoprecipitated from monocyte-derived macrophages (MDMs) supernatants at 12 days postinfection (dpi), and the interacting proteins were identified by mass spectrometry (LC-MS/MS). Serum amyloid p component (SAPC) co-immunoprecipitated with cathepsin B from HIV-infected supernatants triggering neuronal apoptosis. Cathepsin B and SAPC were overexpressed in the brain of HIV-positive patients at different stages of HAND and in patients with Alzheimer's disease. These findings suggest a common mechanism of cathepsin B-SAPC interaction in neuronal death for both HAND and Alzheimer's disease.
Materials and methods
Isolation and infection of monocyte-derived macrophages from HIV-seronegative donors Peripheral blood mononuclear cells (PBMC) were isolated from six healthy women by Ficoll gradient centrifugation. MDMs were selected by adherence and inoculated with HIV-1 ADA at a 0.1 MOI [7] . Supernatants were collected at 3, 6, 9 and 11 dpi to assess the infection measuring the levels of HIV-p24 antigen concentration by ELISA, following the manufacturer's instructions (Express BioTech, Maryland, USA).
Immunoprecipitation of cathepsin B
Uninfected and HIV-infected MDMs were replaced with serum-free RPMI-1640 at 11 dpi, incubated overnight. Supernatants were collected, concentrated and dialyzed overnight at 48C using QuixSep Micro Dialyzer and Cellu SepH1 high-grade tubular dialysis membranes (Membrane Filtration Products, Inc., Seguin, Texas, USA). Total protein concentration was measured by detergent compatible protein concentration assay (DC; Bio-Rad, Hercules, California, USA), and 300 mg was used for immunoprecipitation of cathepsin B using Protein G Dynabeads (Life Technologies, Carlsbad, California, USA) covalently linked to 4 mg of anticathepsin B mAb (Sigma-Aldrich, St. Louis, Missouri, USA) using 20 mmol/l dimethyl pimelimidatex . 2HCl. Protein was eluted with 0.1 mol/l glycine buffer (pH 2.5) and the pH was restored with tris buffer (pH 7.5). Negative control was prepared performing immunoprecipitation with an irrelevant IgG1 isotype. A cathepsin B positive control was generated performing the immunoprecipitation from MDM lysates.
In-solution digestion of immunoaffinity-purified proteins and nanoflow tandem mass spectrometry Co-immunoprecipitation elutes were processed for mass spectrometry as described [20, 21] . Samples were reconstituted in 5% acetonitrile containing 0.1% TFA and analysed by data-dependent analysis using nanoflow LC-MS/MS on an LTQ Orbitrap Velos mass spectrometer (Thermo Scientific). The resulting data were processed and searched using Mascot (version 2.4.0; Matrix Science, London, UK). The Mascot search utilized the human SwissProt database (version 020613, 20 322 entries) and considered peptides at full tryptic specificity, a parent ion mass tolerance of 10.0 ppm and a fragment ion mass tolerance of 0.50 Da. Scaffold (version 4.0.4; Proteome Software Inc., Portland, Oregon, USA) was used to further validate the peptide and protein identifications. Peptide identifications were accepted at least 80.0% probability as specified by the Peptide Prophet algorithm [22] . Protein identifications were accepted if at least 90.0% probability and were assigned by the Protein Prophet algorithm [23] . Proteins that were identified by single peptide matches were included in further analysis. Spectral counts were used as a semi-quantitative tool to compare relevant proteins identified in relation to HIV-1 infection and cathepsin B identification, as postulated [24, 25] . Proteins were analysed as a ratio of spectral counts (HIV/uninfected) by Ingenuity Pathway Analysis (IPA) software (QIAGEN, Redwood City, California, USA), to define the potential cathepsin B interactome. Proteins were selected for validation according to the network generated by IPA, functional relevance and their presence or absence between uninfected and HIV-infected replicates.
Western blots
Protein concentration was measured using a DC assay [7] , and 20-40 mg of total protein was loaded into 4-20% TGX gels (Bio-Rad). Polyvinylidene fluoride (PVDF) membranes were probed with mouse anticathepsin B (1 : 500; Sigma-Aldrich), mouse anti-SAPC (1 : 250; Abcam, Cambridge, UK), mouse anticystatin B (1 : 500; Sigma-Aldrich), rabbit polyclonal antiglyceraldehyde 3phosphate dehydrogenase (GAPDH; 1 : 250; BIOSS, Woburn, Massachusetts, USA) and mouse anti-MMP-9 (1 : 750; R&D systems, Minneapolis, Minnesota, USA), incubated overnight at 48C. HRP-conjugated goat antimouse or antirabbit secondary antibodies (1 : 15 000; Sigma-Aldrich) were incubated for 1 h. For immunoprecipitated samples, a conformation-specific secondary antibody was used [Antimouse IgG VeriBlot for immunoprecipitated secondary antibody (HRP); 1 : 1000; Abcam]. Images were acquired and analysed using ImageLab software (Bio-Rad). Densitometry was performed by dividing the volume (intensity) of each protein by the volume of the GAPDH band for each lane. Membranes were reprobed incubating in Restore Plus Western Blot Stripping Buffer (Thermo Fisher Scientific, Waltham, Massachusetts, USA) for 30 min at 378C followed by washing, blocking and probing with a different antibody. MDM lysates from six donors were used.
HIV-positive patients
Retrospective samples (n ¼ 12) of MDM supernatants from Hispanic women cohort characterized for cognitive function from 2009 to 2012 were used for this study. Samples were collected as part of the R01 project entitled: 'Cystatins and cathepsins in HIV induced neuropathogenesis', with approval from the University of Puerto Rico Medical Sciences Campus Institutional Review Board (Protocol 0720102) and written consents of participants. Inclusion criteria, viral-immune parameters and evaluations of cognitive function have been previously described [8, 26, 27] . According to American Academy of Neurology (m-AAN) criteria, patients were classified into normal cognition, asymptomatic cognitive impairment (A), minor cognitive motor disturbance (MCMD) or HIV-1 associated dementia (HAD).
Enzyme-linked immunosorbent assay SAPC was measured in MDM supernatants from HIV-1 infected and HIV-seronegative individuals from the Hispanic Cohort characterized for HAND [26] , and from supernatants of in-vitro HIV-infected MDM derived from healthy donors at 6 dpi (n ¼ 4 with serum, diluted 1 : 100) and 12 dpi (n ¼ 5 serum-free, diluted 1 : 1000), following manufacturers' instructions (Abcam). Results were normalized using SAPC measured in the culture medium. Pro-cathepsin B, an active precursor of cathepsin B, was measured by ELISA (R&D Systems; n ¼ 8) in serum-free MDM supernatants at 12 dpi, as well as MMP-9 (R&D Systems; n ¼ 5), following manufacturer's instructions.
Cathepsin B activity
Cathepsin B activity from serum-free MDM supernatants at 12 dpi (n ¼ 6) was measured in duplicate using a fluorescent substrate assay kit (Biovision), following manufacturer's instructions and analysed in a VersaFluor TM Fluorometer (Bio-Rad) with 400 nm excitation and 505 nm emission filters.
SK-N-SH neuroblastoma cell cultures
SK-N-SH neuroblastoma (ATCC HTB-11) was cultured in essential modified eagle's medium (EMEM), supplemented with 1% nonessential amino acids, 1% sodium pyruvate, 10% FBS and 1% penicillin-streptomycin. For TUNEL assays, cells were cultured at 1 Â 10 5 cells/well in poly-D-lysine coated eight-well glass chamber slides (Thermo Fisher Scientific), incubated at 378C, 5%CO 2 .
Measurement of apoptosis by terminal deoxynucleotidyl transferase (TdT) dUTP nickend labeling assay Neurons were exposed to MDM serum-free supernatants at 12 dpi (macrophage-conditioned media, MCM) diluted 1 : 4 in plain EMEM and added to neuronal cells at 378C for 24 h as described [7] . MCM was pretreated with specific cathepsin B inhibitor CA-074 (Sigma-Aldrich, 10 mmol/l) or monoclonal anticathepsin B, anti-MMP-9 or anti-SAPC antibodies, either independently or in combination. During apoptosis, fragmented DNA exhibits green fluorescence upon terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL) labelling. A minimum of three images were acquired for each condition for each donor. Green fluorescent nuclei were counted and divided by the total number of neurons (all DAPI-positive nuclei, blue) to obtain a percentage of apoptotic neurons, using ImageJ software (NIH). MCM were collected from MDM from four donors.
Immunofluorescence of postmortem brain tissue Paraffin-embedded postmortem brain tissue samples from healthy and HIV-infected individuals were provided by National NeuroAIDS Tissue Consortium (NNTC) and processed as described before [28] . Mouse monoclonal anticathepsin B (1 : 100; Sigma-Aldrich), mouse monoclonal anti-SAPC (1 : 50; Abcam), rabbit polyclonal anti-ionized calcium-binding adapter molecule 1 (Iba-1) (1 : 100; Wako), mouse monoclonal anti-MMP-9 (1 : 65; R&D Systems), rabbit polyclonal antiamyloid beta 1-42 (Ab) (1 : 50, Abcam) and rabbit polyclonal antineurofilament (1 : 100; Millipore, Billerica, Massachusetts, USA) primary antibodies were incubated overnight at room temperature. Alexa Fluor antimouse 488 and antirabbit 546 fluorescent secondary antibodies (1 : 200; Life Technologies) were incubated at room temperature for 2 h. All sections were labelled with DAPI (1 : 500), diluted in Vectashield (Vector Laboratories, Burlingame, California, USA). Images were acquired using a Nikon Eclipse E400 fluorescence microscope with a SPOT Insight QE camera and SPOT 5.1 software. A minimum of three images were acquired from each section.
Statistical analyses
Wilcoxon's signed rank test was used to compare the presence or absence of peptides in the samples identified by LC-MS/MS (n ¼ 6). Two-tailed unpaired t-tests were used for parametric data and Mann-Whitney tests were used for nonparametric data derived from ELISA and western blot densitometry. SAPC ELISA was analysed by one-way analysis of variance (ANOVA) with Tukey's posttest. For neurotoxicity assays, we used two-way ANOVA with Bonferroni posttest. All statistical analyses were done using Prism GraphPad software 5.0 (GraphPad Software Inc., La Jolla, California, USA) with P value less than 0.05 considered statistically significant.
Results

Identified proteins from uninfected and HIVinfected cathepsin B interactome
Cathepsin B was successfully co-immunoprecipitated from serum-free MDM supernatants at 12 dpi (Supp. Figure 1 , http://links.lww.com/QAD/A759). The procedure was confirmed by identification of cathepsin B peptides in all experimental samples and positive controls and its absence in the negative control by tandem mass spectrometry. A total of 176 proteins had spectral counts with over 90% confidence. From these, 123 proteins that co-immunoprecipitated with cathepsin B were absent from the negative control. Thirty proteins were selected for analyses on the basis of observation rates in the six replicates, when comparing HIV-infected with uninfected MDM supernatants. The spectral counts from nine proteins, functionally relevant based on the literature, are included in Fig. 1a . Many of these proteins were based on single-peptide identifications and did not meet the typical two-peptide (per protein) identification criteria. However, many of these single-hit proteins were considered, as they were consistently observed across two or more of the six replicates. In most single-hit proteins selected, there was a difference of replicates positive for the protein between the conditions (uninfected vs. HIV-infected). The predicted network of interactions generated by IPA software is described in Fig. 1b . The proteins that coimmunoprecipitated with cathepsin B in HIV-positive samples and not in uninfected MDM are colored in green; proteins colored in red were co-immunoprecipitated with cathepsin B in uninfected samples but not in HIVpositive samples. Proteins colored in yellow were identified equally in both uninfected and HIV-positive samples. Proteins in blue were not identified in our dataset, but were provided by the software to connect the proteins identified in the network. High-density lipoprotein (HDL) and complement proteins are important central hubs of proteins identified. The IPA software catalogued the following diseases related to co-immunoprecipitated proteins: developmental disorders, hereditary disorders, immunological diseases, humoral immune response, inflammatory response and neurological diseases (Supp. Figure 2 , http://links.lww.com/QAD/A759). The acute phase response signalling was the most relevant canonical pathway that correlated with cathepsin B functions and the proteins identified. The IPA analysis provided a new link between MDMderived cathepsin B in HIV infection and the activation of lipids, complement system and inflammation-related proteins that are observed during the infection and may converge in neuronal apoptosis. SAPC co-immunoprecipitated in four of the six HIV-infected MDM supernatants, although it was not detected in uninfected MDM supernatants (Fig. 1c) . Therefore, we hypothesized that SAPC is involved in neuronal death when bound to cathepsin B during HIV infection. Cathepsin B-MMP-9 co-immunoprecipitate was identified in two of the uninfected samples but not in HIV-positive samples.
Validation of the proteins interacting with cathepsin B by western blot
We validated the co-immunoprecipitation of SAPC in HIV-infected samples by western blot (Fig. 2a ). Coimmunoprecipitation of cystatin B with cathepsin B was decreased in HIV-infected MDM supernatants, consistent with our previous reports of disrupted interaction after HIV infection of MDM [7] . MMP-9 was detected only in uninfected, immunoprecipitated samples, also validating the mass spectrometry results.
Detectable levels of SAPC and MMP-9 were observed in MDM lysates (Fig. 2c ) that were secreted to culture supernatants at 12 dpi (Fig. 2b) . In serum-free supernatants, no visual difference was observed in any of the proteins. Cystatin B was not detected in MDM serumfree supernatants. None of the proteins tested were statistically significant comparing uninfected with HIVinfected MDM lysates, according to densitometry analyses (Fig. 2d ).
Cathepsin B secretion is higher in HIV-infected macrophage supernatants but not serum amyloid P component or matrix metalloprotease-9 SAPC concentration was not statistically different in MDM supernatants from HIV-seropositive women, compared with healthy women (P ¼ 0.890) even when subdivided by cognitive status (P ¼ 0.968), although there seems to be a tendency to increase in cognitively impaired HIV-infected patients (Supp. Figure 3 , http://links.lww.com/QAD/A759). We did not observe differences when comparing uninfected with HIV-infected MDM supernatants infected in vitro at 6 dpi (P ¼ 0.686).
Cathepsin B secretion is significantly increased in HIVinfected MDM (P < 0.001) at 12 dpi (Fig. 3a) , which constitute the macrophage-conditioned media (MCM) used for neurotoxicity experiments. However, SAPC and MMP-9 secretion were not altered in HIV-infected MDM (P ¼ 1.00 and P ¼ 0.691, respectively) (Fig. 3b, c) . Cathepsin B activity is slightly increased in HIV-infected MDM serum-free supernatants, but was not statistically significant (P ¼ 0.26, Fig. 3d ).
Cathepsin B-serum amyloid P component interaction in HIV-1 infected monocyte-derived macrophage secretome contributes to neuronal apoptosis Neurons were exposed to uninfected or HIV-positive MCM with or without antibodies against cathepsin B, SAPC and MMP-9. SAPC and MMP-9 antibodies were tested individually or together with cathepsin B antibody, to assess the neurotoxic effect of targeting both proteins simultaneously (Fig. 4 ). We confirmed that productively HIV-infected MCM (Supp. Figure 4 Alzheimer's disease by immunofluorescence of snap frozen brain tissue [7] . Here, we report an overexpression of cathepsin B, cystatin B and cystatin C in the frontal white matter of three patients with HAND (Fig. 5a) . Cathepsin B and cystatin B [28] are also increased in HIVsubsyndromic tissues, while cystatin C is absent at this stage of the disease. Cystatins have low expression in Alzheimer's disease tissues (data not shown). Cathepsin B is increased and shows colocalization with microglia/ macrophage marker Iba-1 in Alzheimer's disease tissue. MMP-9 colocalized with Iba-1 in HIV-subsyndromic tissue, but was not detected in HAD or Alzheimer's disease. SAPC is increased in the brain of HIVE/HAD and Alzheimer's disease patients. We observed immunolabelling of Ab in HIV-subsyndromic and HIVE/HAD tissues in addition to the expected Ab in the Alzheimer's disease tissue. SAPC colocalized with neurofilament in HIVE/HAD to a higher degree than what is observed in Alzheimer's disease (Fig. 5b) . Negative controls demonstrated low unspecific labelling.
Discussion
In this study, we aimed to determine the role of secreted cathepsin B interactome in HIV-1 infection and neurotoxicity. We report nine proteins that co-immunoprecipitated with cathepsin B in uninfected or HIV-infected MDM. The low number of spectral counts found in these proteins is likely due to the low concentration of protein in the final co-immunoprecipitated eluate. However, IPA analysis revealed the connection between these proteins and confirmed functions related to cathepsin B including modification of the extracellular matrix, processing of APP, amyloidogenesis, activation of proteases and immune response.
From the proteins identified, SAPC co-immunoprecipitated from four HIV-infected and none of the uninfected MDM supernatants. SAPC is involved in acute phase response and is linked to amyloid plaque accumulation by stabilizing amyloid fibrils, thus preventing their degradation [29, 30] . It is present in Alzheimer's disease patients [31] , and induced neuronal apoptosis when injected into rat hippocampus [32] . There is proof of efflux of SAPC at the BBB [33] , and accumulation of SAPC in the brain of rats with permeabilized BBB, demonstrating its role in neurodegenerative diseases. As the BBB is also compromised in HAND [3, 34, 35] , it is important to understand the link between cathepsin B-SAPC and neurodegeneration during HAND development.
To examine the clinical relevance of SAPC in HAND, its concentration was measured in supernatants of macrophages from HIV-infected women under antiretroviral therapy. SAPC did not show differences when stratified by cognitive function. However, inhibition of SAPC, cathepsin B or both proteins from HIV-infected MCM before addition to neurons was neuroprotective. Previous reports indicated that SAPC possess neurotoxic properties [32] , including the stabilization of amyloid fibrils, which is the hallmark of Alzheimer's disease neurodegenerative process [31] . These results suggest that HIV-1 infection is promoting the association of SAPC with cathepsin B rather than a change in SAPC expression or secretion to increase neurotoxicity.
MMP-9 co-immunoprecipitated with cathepsin B only from uninfected supernatants. Inhibition of MMP-9 from HIV-infected MCM was not neuroprotective. Studies suggest that MMP-9 can degrade extracellular amyloid peptides [36] [37] [38] , which might explain the negative effect of inhibiting this protein in MCM before exposure to neurons. evidence of its role in the disease. We are reporting a novel role for SAPC in HAND with its colocalization with neurofilament in HIVE/HAD tissues. Recently, a mechanism of intraneuronal amyloid accumulation was described in a transgenic mice model expressing HIV-1 gp120, amyloid precursor protein (APP) and presenilin-1 (PS1). In this model, gp120 triggers accumulation of APP and beta-secretase (BACE1) with subsequent accumulation of Ab peptides in the lysosomes of neurons [39] . Amyloid aggregation has been described in the brain of HIV-infected patient carriers of the apolipoprotein E allele 4 (ApoE4) [40] . The expression of APP has been observed in the surface of circulating monocytes from HIV-infected patients, but it was not a successful biomarker for neurocognitive impairment [41] . As cathepsin B and SAPC have been linked to amyloid plaque formation and stabilization [10, 12, 13, 29, 30, 40, [42] [43] [44] , both proteins might be triggering amyloid plaque formation among other molecular imbalances in HIV-positive patients, therefore contributing to neuronal dysfunction and death. Another possible mechanism is the interaction of SAPC with Fcg receptors [45] , that are involved in Ab-mediated neurotoxicity and development of Alzheimer's disease [46, 47] .
In future studies, we plan to determine whether SAPC and MMP-9 interactions with cathepsin B are present in microglia supernatants, as cathepsin B secreted from HIVinfected microglia is also neurotoxic in vitro [28] Second, all our studies have been conducted using women donors to compare with our Hispanic women cohort characterized for HAND. Additional studies will be performed using male PBMCs. In our study, we did not use growth factors to differentiate monocytes. Although granulocyte-macrophage colony-stimulating factor (GM-CSF) differentiates macrophages into a pro-inflammatory state (M1 type), macrophage colony-stimulating factor (M-CSF) differentiates macrophages into an anti-inflammatory state (M2 type), with different cytokine profiles [48] [49] [50] [51] [52] . The secretion of cathepsin B and interacting partners can be studied by inducing a specific polarization. In this study, we decided to allow the macrophages to adhere in culture and observe the changes in morphology induced by HIV-1 infection. In agreement with the literature, we observed a mixture of round and spindle-shaped macrophages in cultures from all healthy PBMC donors [48] and similar concentration of cathepsin B in MDM supernatants across the cultures. Finally, we used the HIV-1 ADA strain, which productively infects MDM in vitro, to elucidate mechanisms triggered by the infiltration of macrophages into the CNS of HIV-positive patients. However, it is in our interest compare these results with those obtained when microglia or MDM are infected with a viral strain isolated directly from the brain [53] .
Cathepsin B inhibitors CA-074 and E64d are currently under study as therapeutic candidates for treatment of Alzheimer's disease, reduction of amyloid plaque formation and improvement of cognitive function [12, 42] . These results might shed light on mechanisms shared by Alzheimer's disease and HAND, for which common pathways are currently under study ( [54, 55] and reviewed in [56] ). Targeting cathepsin B-SAPC complex upon HIV-1 infection may represent a novel strategy for drug development against HAND.
